tbuckley/cabot-search huggingface dataset:
Abstract 3077: TMPRSS2-ERG regulation of miRNA in prostate cancer.
Authors: Jung Kim, Longtao Wu, Hong-Jian Jin, Jonathan Zhao, Jindan Yu
Journal: Cancer Research (2013)

Abstract Prostate cancer is the cause of the second highest number of cancer related deaths in men in the United States, with the highest number of new estimated cases every year. In addition, the survival rate in localized and regional prostate cancer is 100%, while metastatic prostate cancer is about 29%, with a wide spectrum of biological deregulations. MicroRNA (miRNA) is a small non-coding RNA, about 22 nucleotides long, that mostly targets the 3’UTR of a gene for translational repression or mRNA degradation. More recently, miRNAs have been shown to play an important role in tumorigenesis, cancer progression, and metastasis. MiR-200c is one of the miRNA widely studied in cancer, as it has a role in regulating epithelial-mesenchymal transition (EMT). One of the ways in which miR-200c inhibits EMT is through its ability to downregulate ZEB1, an EMT activator that primarily functions by repressing E-cadherin. ERG is a transcription factor that is often fused with TMPRSS2 in prostate cancer and promotes cancer progression. In our study, we investigated the interaction of ERG and miR-200c, two factors that play important role in cancer progression, in prostate cancer. First, we identified ERG regulated miRNAs through utilizing miRNA profiling in LNCaP cells that were overexpressing ERG and in VCaP cells that have ERG knocked down. We selected miRNAs that are repressed upon ERG overexpression and derepressed upon ERG knockdown and also overlapped the results with ERG ChIP-seq data to identify ERG regulated miRNAs. Through this process we discovered that miR-200c is a good ERG-targeted miRNA. To validate the bioinformatics results, we used ERG overexpression in LNCaP and ERG knockdown in VCaP to measure mature miR-200c levels by miRNA assay. In addition, ERG ChIP-qPCR and miR-200c promoter luciferase assays showed that ERG binds at the miR-200c promoter. Next, to identify functional roles of miR-200c in ERG overexpressed cells, we performed invasion and migration assays to show that miR-200c plays an important role in the inhibition of ERG-mediated cancer progression. This study identifies an important factor, miR-200c, whose loss mediates the progression of TMPRSS2:ERG fusion-positive prostate cancer. According to our results, it might be possible to use miR-200c as a future therapeutic for ERG positive patients. This work was supported in part by the Research Scholar Award RSG-12-085-01 (to J.Y.) from the American Cancer Society, Department of Defense PC080665 (to J.Y.) and NRSA pre-doctoral fellowship T32 CA080621 (to J.K.). Citation Format: Jung Kim, Longtao Wu, Hong-Jian Jin, Jonathan Zhao, Jindan Yu. TMPRSS2-ERG regulation of miRNA in prostate cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3077. doi:10.1158/1538-7445.AM2013-3077
CANCER DE COLON PERDIDO AL DIAGNOSTICO. ¿HEMOS APRENDIDO ALGO?
Authors: F Igea, J Barcenilla, K De Jesus Geneaux, S Castillo Rocío
Journal: Endoscopy (2013)

Introducción: El cáncer de colon perdido al diagnóstico, cáncer de intervalo como también es conocido, ha constituido un tema de preocupación para la endoscopia. Realizamos un estudio de incidencia en nuestro medio hace más de tres años y nos planteamos evaluar nuestra mejora. Objetivos: Determinar la frecuencia actual de cáncer de intervalo en nuestro medio y compararla con la encontrada hace tres años. Analizar lascausas de los fallos de detección y plantear estrategias de mejora. Material y Métodos: Analizamos los canceres de colon diagnosticados en el periodo 01/07/12 – 01/07/13. Determinamos frecuencia de colonoscopias previas en los últimos 3 y 5 años, errores de protocolo, errores en exploración previa, y estadiaje de los tumores perdidos al diagnóstico. Comparamos la incidencia actual con la previamente calculada en nuestro grupo. Resultados: Hemos detectado 155 canceres de colon. 4 tenían colonoscopia previa en menos de 3 años (2,5%) y 11 en menos de 5 años (7,09%). 3 facultativos implicados en 7 casos tienen la menor tasa de detección de adenomas. 10 colonoscopias previas no exploraron íleon (8 de los tumores eran de colon derecho y al menos 3 en válvula ileocecal). Existió error al aplicar el protocolo en 6. 2 casos fueron T2N0, 5 T3N0 existiendo afectación ganglionar en los 4 restantes. 5 de los casos (45%) eran mayores de 80 años. Nuestra frecuencia de canceres de intervalo (2,5%) resulto idéntica a la publicada. Conclusiones:
DNA and the Genetic Code
Authors: Nadia Rosenthal
Journal: New England Journal of Medicine (1994)

Forty years after the discovery of the double helical structure of DNA, it is still remarkable that this deceptively simple molecule specifies virtually everything about the form and function of all cells and all organisms. The way DNA stores its code of life and passes it on from one generation to the next is the key to the puzzle of how mutations cause cell dysfunction and disease. And within DNA resides the means for new medical interventions through gene therapy.This article on the structure of DNA is the first of four brief reviews of the principles and techniques of . . .
THU0597 Effectiveness of a Group-Based Intervention to Improve Medication Beliefs and Adherence in Non-Adherent Patients with Rheumatoid Arthritis: A Randomized Controlled Trial
Authors: H. Zwikker, C. Van den Ende, S. Van Dulmen, W. Van Lankveld, A. Den Broeder, F. Van den Hoogen, B. Van de Mosselaar, B. Van den Bemt
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Medication adherence in patients with rheumatoid arthritis (RA) is suboptimal, with adherence rates between 30% to 80%. Existing interventions to improve medication adherence are mostly complex and have small effect sizes. We therefore developed a short, group-based intervention to change the balance in necessity and concern beliefs about medication, and to improve adherence to Disease Modifying Anti Rheumatic Drugs (DMARDs) in non-adherent RA patients. <h3>Objectives</h3> This randomized clinical trial assessed the effect of a group-based intervention on patients’ balance in beliefs about medication (primary outcome, measured with the BMQ: beliefs about medicine questionnaire), and medication adherence. <h3>Methods</h3> Adult, non-adherent (determined with the CQR: Compliance Questionnaire on Rheumatology) RA patients using DMARDs were randomized into the intervention arm, consisting of two motivational interviewing based group sessions led by a pharmacist, a homework assignment, and a follow-up call, or into the control arm, in which participants received brochures about their currently used DMARDs. Measurements were conducted at baseline, and at one week, six months and 12 months follow-up. Generalized Estimating Equations were used to estimate intervention effects. <h3>Results</h3> 123 patients, (mean age: 60 years, 69% female) were randomized. No differences in improvement in medication adherence, and in the change in the balance between necessity and concern beliefs about medication were detected between the two arms. Only at 12 months follow-up, participants in the control arm had stronger necessity beliefs about medication than participants in the intervention arm (b and 95% CI indicating this difference, corrected for baseline and with control group as reference category: -1.1 (-2.0 - -0.2)). <h3>Conclusions</h3> Our group-based intervention neither changed the beliefs about medication, nor improved medication adherence to DMARDs in non-adherent patients with rheumatoid arthritis. <h3>References</h3> Van den Bemt BJF, Zwikker HE, Van den Ende CHM (2012). Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev. Clin. Immunol. 8(4), 337–351. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; CD000011. Zwikker H, Van den Bemt B, Van den Ende C, Van Lankveld W, Den Broeder A, Van den Hoogen F et al. (2012). Development and content of a group-based intervention to improve medication adherence in non-adherent patients with rheumatoid arthritis. Patient Education and Counseling, 89: 143–151. <h3>Disclosure of Interest</h3> None Declared
Poster session 5. Translational research
Authors: C. Robichon, J. P. Annereau, B. Gomes, A. Pillon, L. de Vries, D. Cussac, N. Meyer, L. Lamant, A. Kruczynski, N. Guilbaud, J. Kluza, M. Jendoubi, P. Corazao-Rozas, F. Andre, A. Jonneaux, P. Guerreschi, P. Formstecher, L. Mortier, P. H. I. Marchetti, E. Bozkurt, H. Atmaca, S. Uzunoglu, R. Uslu, B. Karaca, J. Erenpreisa, T. R. Jackson, A. Huna, K. Salmina, I. Innashkina, E. Jankevics, P. A. Townsend, M. S. Cragg, H. Atmaca, E. Bozkurt, S. Uzunoglu, R. Uslu, B. Karaca, S. P. Ramos, M. Bin, M. D. S. Neto, R. Curvello, A. C. S. de Souza, M. Nunes, L. B. Weiswald, P. Vrignaud, S. Vacher, E. Turlotte, S. Richon, S. Roman-Roman, I. Bieche, V. Dangles-Marie, F. Morais-Santos, C. Pinheiro, A. Vieira, F. Schmitt, J. Paredes, F. Baltazar, T. Zhang, Y. W. Lee, Y. F. Rui, T. Y. Cheng, G. Li, K. H. Sreelatha, R. S. Reshma, S. Veena, S. N. Rakesh, S. Thara, P. Jem, S. Priya, S. Veena, K. H. Sreelatha, R. S. Reshma, S. N. Rakesh, S. Priya
Journal: Annals of Oncology (2013)
PWE-105 Biological World Of Ibd, Is It Only Safe In Tertiary Care Centres?
Authors: S Kadir, R Campbell, N Ahluwalia
Journal: Gut (2014)

<h3>Introduction</h3> Inflammatory bowel disease (IBD) has a prevalence of 400 per 100,000 with approximately 240,000 patient with IBD in UK. It is triggered by a combination of environmental, genetic and immunoregulatory factors including a dysfunctional mucosal immune response. In the last 15 years, the introduction of biologicals has dramatically changed the landscape with improving natural history and outcome of IBD. Many multi-centre trials have confirmed the efficacy of both Infliximab (IFX) and Adalimumab (ADA) in the management of IBD. These drugs are however not without side effects and need close monitoring in specialist IBD clinics. We share our experience from a large-sized DGH [&gt;400,000 population] in Northwest England with a dedicated IBD service and experience in the use of biologicals in IBD patients since 2000. <h3>Methods</h3> We interrogated and audited our IBD data base and collected all the patients who were or had been on biologicals. The data goes back to the year 2000. <h3>Results</h3> The basic demographics showed total of the 90 patients; 42% female. The mean age was 42.4 (female) vs. 39.3 yrs (male). Age at the time of diagnosis of IBD was 31.1 yrs for females and 32.4 years for males. 53% had crohn’s disease and rest were UC. Patients with UC had higher body weight vs. crohn’s disease with a mean of 76.1 vs. 67.6 kg respectively. 58% had Ileoceacal Crohn’s of which 73% were males. 62.5% of females with UC had pan colitis vs. 42% males. All patients were fully informed and consented prior to the initiation of biological therapy. 89% of the patients were on immunomodulators prior to biological therapy. 93% of the patients with UC were on infliximab with 5% on Adalulimab. 1 pt was on Basiliximab which was changed to infliximab. Those with crohn’s disease, 83% were on Infliximab and 17% on Adalulimab. Infliximab was stopped in 30% due to either no further clinical need or change to Adalulimab and of these 6% due to adverse events. In the ADA group 2% stopped due to lack of clinical inefficacy. The median duration of biologicals was 38.2 months, maximum duration 156 months. <h3>Conclusion</h3> In the context of IBD, biological drugs in a dedicated IBD service are highly efficacious. In our centre, paucity of adverse event maybe due to our cohort of patient population with little background incidence of TB. In contrast to the UK IBD audit, we had more usage of biologicals in the context of UC, of which 50% had pan colitis. Our experience shows that a treating IBD effectively and safely requires a dedicated service as outlined in BSG guidelines for IBD, and not necessarily a tertiary care referral! <h3>Disclosure of Interest</h3> None Declared.
AB0597 Prevalence of diagnosed osteoarthritis attributable activity limitation among adults with and without diagnosed diabetes: caracas venezuela
Authors: L. J. Ascanio, Vera Carlos, Brakamonte Marlen
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Is there a link between diabetes and arthritis? Using data from the 2010-2012 in our endocrinologycal foundation in Caracas Venezuela Interview Survey, Lunar and colleagues estimated the prevalence of osteoarthritis among 6,542 adults older than 18 years who did and did not have diabetes. In addition, they reported the prevalence of osteoarthritis-attributable activity limitation (OAAL) among persons with osteoarthritis, also by diabetes status. All data were self-reported. <h3>Objectives</h3> Diabetes was defined as survey respondents saying that they had ever been told they have diabetes. osteoarthritis was defined as respondents having ever been told they had some form of arthritis, gout, lupus, or fibromyalgia, and OAAL was defined as being limited in any way by osteoarthritis or joint symptoms. The study compared 3489 people with diabetes and 3,053 individuals without diabetes and included analyses by age group, sex, race/ethnicity, education level, body mass index (BMI), and physical activity level. <h3>Methods</h3> Of all persons with diabetes, 48% reported having osteoarthritis, compared with 20% of persons without diabetes. However, adults with diabetes were significantly older (60 vs 45 years), but even after adjustment for age, the prevalence of osteoarthritis was 51% higher among adults with diabetes. In fact, the prevalence ratio was highest among the youngest age group, 18-44 years, among whom 22.7% of diabetic adults reported arthritis compared with 7.2% of nondiabetic adults. <h3>Results</h3> After adjustment for age, sex, race/ethnicity, education level, BMI, and physical activity level, adults with diabetes had a 44% higher risk for prevalent osteoarthritis than those without diabetes. Moreover, 55% of osteoarthritic individuals with diabetes reported that their osteoarthritis limited their activities, compared with 39% of nondiabetic persons with osteoarthritis. Multivariate adjustment attenuated this relationship, but OAAL was still 21% higher among diabetic adults with osteoarthritis than in nondiabetics. <h3>Disclosure of Interest</h3> None Declared
Abortion laws cause problems in Poland
Authors: M. Gajewski
Journal: BMJ (1995)

A doctor who performed an abortion in Poland faces two years in prison and the loss of his medical license for up to 10 years if he is found guilty of violating the new abortion laws introduced in 1993 after a lengthy campaign by the Catholic church and the Christian Democratic Union party. The new laws permit abortion when the pregnancy threatens the life of the mother, presents a serious health threat to the mother, is the result of rape or incest, or will result in the birth of a irreversibly and seriously malformed fetus. In this case, the woman had the abortion because she could not afford to support the child on her own; her former lover faces two years in prison if he is convicted of having paid for the operation. The new law follows a 40-year period of liberal abortion laws under the communist regime when abortion was seen as a form of contraception; an estimated 100,000 abortions occurred in the 1980s. The number of recorded abortions decreased to 777 (nine were in contravention of the law) in 1993. However, some abortions have gone underground; this one surfaced because of an angry former lover. Doctors can now charge two months' salary for the illegal operation, forcing many of the women go to Russia, Belarus, or the Ukraine where the operation is cheaper. Other women take matters into their own hands; one woman murdered the baby she would have aborted earlier.
Newspaper Citations of JNCI Increase
Authors: J. Johnston
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Newspaper Citations of JNCI Increase Get access Jana Johnston Jana Johnston Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 18, 18 September 1991, Page 1292, https://doi.org/10.1093/jnci/83.18.1292 Published: 18 September 1991
Abstract 5065: Phosphorylation of Peptidyl prolyl isomerase 1 by Mixed Lineage Kinase 3 promotes breast cancer pathogenesis
Authors: Rajakishore Mishra, Gautam Sondarva, Anumantha Kanthasamy, Basabi Rana, Ajay Rana
Journal: Cancer Research (2010)

Abstract MLK3 is a member of MLK sub-family that belongs to the family of MAP kinase kinase kinase (MAP3K). The MLK family members are characterized by the presence of signature sequences of Ser/Thr and Tyr kinases within their catalytic domain. The detailed physiological function of MLK3 is yet to be deciphered fully, however the available data suggest that in neuronal cells, MLK3 plays role of a pro-apoptotic kinase. The function of MLK3 in any type of cancer is not known. Interestingly the C-terminal tail of MLK3 contains consensus sequences for various protein-protein interactions and phosphorylation sites for numerous kinases. The C-terminal tail also contains Ser/Thr-Pro sequence, a consensus sequence for prolyl isomerase (Pin1), which has been reported to be over-expressed in cancer cells, including in breast cancer cells and primary tumors. Our initial hypothesis was that probably Pin1 binds to MLK3 and regulates MLK3's kinase activity. Our in vivo binding indeed suggested that Pin1 binds to MLK3 via PPI domain robustly and to certain extent through WW domain. The binding of Pin1 did not alter the kinase activity of MLK3. Interestingly, counterintuitive to our initial hypothesis, we observed that MLK3 was able to phosphorylate Pin1 and alter Pin1's isomerase activity. We also identified S138 as a phosphorylation site on Pin1 and raised p-S138 antibody. Since, Pin1 is known to drive G2-M-cell cycle transition, we examined whether phosphorylation of Pin1 promotes cell cycle progression. Our data indicated that phospho-S138 Pin1 increased the G2-M transition of cell cycle. Pin1 is reported to be a nuclear protein; however it is not known whether this translocation of Pin1is regulated by any protein. We observed that Pin1 was translocated to nucleus upon phosphorylation by MLK3 at S138 site and the phospho-S138 Pin1 was highly expressed in breast cancer cell lines and tumors, compared to non-transformed breast epithelial cell line and normal breast tissues respectively. The breast cancer tissue arrays analyzed also showed that phospho-S138 was highly expressed in tumors compared to normal breast tissue and the intensity of staining was significantly higher in tumors as well. Taken together, our data suggest that phosphorylation of Pin1 by MLK3 drives G2-M transition and promote breast cancer pathogenesis. Thus targeting MLK3 or Pin1 may prove beneficial to control breast cancer tumorigenesis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5065.
Tips for a Physician in Getting the Right Job, Part XXIV
Authors: Jay A. Harolds
Journal: Clinical Nuclear Medicine (2015)

Doctors can be fired for many reasons including poor productivity, poor quality work, complaints from patients or colleagues, differences of opinion with practice leaders, not being professional, not being up to date in knowledge, not doing enough scholarly work, or to factors beyond his/her control. The cause(s) for being terminated and how gracefully the individual left the practice will have an important bearing on how successful the physician will be in finding a new position. If let go, the doctor must not become negative, but must reassess his/her career and life goals, and plan carefully for the future.
Induction of Ovulation and Fertility in Amenorrheic Women by Pulsatile Low-Dose Gonadotropin-Releasing Hormone
Authors: David M. Hurley, Rhonda Brian, Ken Outch, Jan Stockdale, Annette Fry, Charles Hackman, Iain Clarke, Henry G. Burger
Journal: New England Journal of Medicine (1984)

In functional hypothalamic amenorrhea, failure of ovulation probably results from deficient hypothalamic secretion of gonadotropin-releasing hormone (GnRH). We treated 14 infertile women in whom this condition was resistant to clomiphene with pulses of 5 to 15 micrograms of GnRH administered subcutaneously by portable pumps at 90-minute intervals in 36 cycles of treatment. Ovulation occurred in 30 cycles (83 per cent) and was followed by normal luteal function in 24. Singleton pregnancy occurred after 13 (54 per cent) of these cycles. Ovarian ultrasound consistently showed a single dominant follicle, and follicular-phase levels of gonadotropins and urinary estrone glucuronide were in the normal range in all cycles of treatment except two in which mild ovarian overstimulation occurred. Plasma profiles of GnRH and luteinizing hormone were highly pulsatile after subcutaneous administration of GnRH, and mean peak plasma levels of GnRH were comparable to those in pituitary portal blood. We conclude that treatment with low-dose subcutaneous pulses of GnRH is a safe, effective, and physiologic method of restoring reproductive function in hypothalamic amenorrhea and that it has advantages over gonadotropin therapy.
Molecular evolution of a Y-chromosomal repetitive sequence family in the genus Mus.
Authors: Y Nishioka, B M Dolan, L Zahed, V Prado, H Tyson
Journal: Molecular Biology and Evolution (1994)

A 522-base-long Y-chromosomal sequence was isolated from a BALB/c genomic library and was designated "BF046." It is repeated about 200 times in the male genome, and a difference was detected between the Mus musculus musculus and the M. m. domesticus type Y chromosomes. BF046-related sequences were present over the entire length of the Y chromosome as visualized by in situ hybridization. Southern blot analysis against DNAs isolated from eight species in the genus Mus showed that BF046-related sequences were amplified in the Y chromosomes of three closely related species: M. musculus, M. spicilegus, and M. spretus. To gain insight into the stability of the BF046 sequence family, we isolated 18 additional clones from these three mouse species and compared their sequences. The M. musculus sequences differed from the M. spicilegus and M. spretus sequences by two indels. The remaining parts of the sequences were very similar, but both parsimony and distance-based analytical methods divided the sequences into the same four subgroups, with each species having its own subgroup(s). Thus, the Y chromosomes of M. musculus, M. spicilegus, and M. spretus can be distinguished from one another.
FUNCTIONAL TRICUSPID REGURGITATION AFTER SURGICAL REPAIR OF PROLAPSE-RELATED MITRAL REGURGITATION: EARLY TO MID-TERM RESULTS FROM A LARGE PROSPECTIVE COHORT ANALYZED BY THREE-DIMENSIONAL TRANSESOPHAGEAL ECHOCARDIOGRAPHY
Authors: Chiara Sordelli, Giovanna Di Giannuario, Guido Carlomagno, Emanuela Alati, Michele De Bonis, Ottavio Alfieri, Giovanni La Canna
Journal: Journal of the American College of Cardiology (2015)